“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
Tecan Group (SIX Swiss Exchange: TECN) and Thermo Fisher Scientific (NYSE: TMO), a global leader in the service of science, today announced a collaboration to enable COVID-19 testing worldwide. Thermo Fisher Scientific introduces a new highly automated real-time PCR solution designed to analyze up to 6,000 samples in a day without getting married to meet the growing global demand for COVID-19 testing. The high-speed formula allows labs to double or even triple their ability to test global efforts to get communities back to paintings and school.
The formula includes tools from the Tecan Fluent family of lab workstations, the highest strength platform in Tecan’s extensive portfolio of liquid handling solutions for lab automation and Introspect software, a tool and software to analyze and report consumable use.
Thermo Fisher Scientific Amplitude Solution is a molecular diagnostic verification formula that operates the company’s Applied Bioformulas QuantStudio 7 tools as well as Tecan’s liquid handling products. The modular solution provides verification effects in a four-step procedure that requires practical time, a laboratory area, and a minimum workers’ body.
Tecan’s CEO, Dr. Achim von Leoprechting, said: “We are very pleased to have married Thermo Fisher Scientific, supporting efforts to develop additional COVID-19 functions with our Fluent workstation and Introspect software. At this unprecedented time, we are passionately contributing to foreign efforts to change the course of COVID-19 through the empowerment of clinical and clinical communities to drive research, help detect remedies, and intensify globalArray
“Increasing verification functions is an essential component of any community’s plan to reopen schools and businesses,” said Marc N. Casper, president, president and ceo of Thermo Fisher Scientific. “Current approaches to accentuating verification require abundant resources and staff. This more automated, high-speed solution will allow labs around the world to accumulate verification volumes and get their verification effects faster.”
The Amplitude solution uses Thermo Fisher’s Applied Biosystems TaqPath COVID-19 combo kit, a fast and very delicate multiple diagnostic control that checks the doses and controls needed for the qualitative detection of nucleic acid of SARS-CoV-2, the guilty COVID-19 virus. The company will introduce this new end-to-end solution to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (U.S.) and plans to download more records globally.
As a component of this offering, Amplitude Solution consumers will enter into a source agreement with Thermo Fisher to ensure an initial, proven and reliable source of reagents and consumables. With the support of Thermo Fisher’s committed visitor 24/7, the end-to-end solution, which adds reagents, consumables and verification kits, can be obtained from a single source.
For more information about the Amplitude solution, visit www.thermofisher.com/amplitude.
About Tecan Tecan (www.tecan.com) is one of the world’s leading suppliers of laboratory tools and responses in the fields of biopharmaceuticals, forensic medicine and clinical diagnosis. The corporation specializes in the progression, production and distribution of automation responses for laboratories in the life sciences sector. Its clients come from pharmaceutical and biotechnological companies, departments of university studies, forensic and diagnostic laboratories. As a manufacturer of original devices (OEM), Tecan is also a leader in the progression and manufacture of OEM tools and parts that are then distributed through partner companies. Founded in Switzerland in 1980, the company has manufacturing, study and progression plants in Europe and North America and maintains a sales and service network in 52 countries. In 2019, Tecan generated sales of 637 million Swiss francs (US$643 million; 574 million euros). Tecan Group’s registered shares are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world’s leading scientific company with annual sales of more than $25 billion. Our project is to enable our consumers to make the world healthier, cleaner and safer. Whether our clients are accelerating life science research, solving complex analytical challenges, getting better diagnostics and therapies for patients, or expanding the productivity of their labs, we’re here for them. Our global team of over 75,000 colleagues offers an unprecedented combination of cutting-edge technologies, convenience and pharmaceutical facilities through our industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, visit www.thermofisher.com.
For information:
Tecan Group Martin BrendleVice President of Corporate Communications and IRTel. (0) 44922 30 Fax -41 (0) 44922 88 [email protected]
Attachment file
press release